| Zacks Company Profile for Swedish Orphan Biovitrum (BIOVF : OTC) |
|
|
| |
| • Company Description |
| Swedish Orphan Biovitrum is a biotechnology company. It develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company's product portfolio consists of Core Products segment which offers pharmaceuticals within Inflammation area and Genetics and metabolic therapeutic area; Partner Products segment which offers pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The company operates primarily in Sweden, Denmark, Finland, Norway, United Kingdom and France. Swedish Orphan Biovitrum is based in Solna, Sweden.
Number of Employees: 1,772 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $30.50 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 96 shares |
| Shares Outstanding: 356.00 (millions) |
| Market Capitalization: $10,858.00 (millions) |
| Beta: 0.50 |
| 52 Week High: $32.25 |
| 52 Week Low: $24.08 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
14.92% |
6.96% |
| 12 Week |
0.07% |
8.11% |
| Year To Date |
10.27% |
14.51% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Guido Oelkers - Chief Executive Officer
Annette Clancy - Chair of the board of directors
Henrik Stenqvist - Chief Financial Officer
Torbjorn Hallberg - General Counsel & Head of Legal Affairs
Lena Bjurner - Head of Human Resources
|
|
Peer Information
Swedish Orphan Biovitrum (CORR.)
Swedish Orphan Biovitrum (RSPI)
Swedish Orphan Biovitrum (CGXP)
Swedish Orphan Biovitrum (BGEN)
Swedish Orphan Biovitrum (GTBP)
Swedish Orphan Biovitrum (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: W95637117
SIC: -
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/15/25
|
|
Share - Related Items
Shares Outstanding: 356.00
Most Recent Split Date: (:1)
Beta: 0.50
Market Capitalization: $10,858.00 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/15/25 |
|
|
|
| |
